Medivir

Contact
medivir.se
+46854683100

Medivir AB

Lunastigen 7, PO Box 1086
141 22 Huddinge
Sweden
+46854683100
medivir.se
Contact
Profile News
Contact

About Medivir

Medivir's objective is to be a profitable research-based pharmaceutical company with an in-house sales function for specialist products on the Nordic market. Medivir aims to develop protease inhibitors to innovative pharmaceuticals against major widespread diseases and improve the quality of life for a number of patient groups.

Read more about Medivir
Facts about Medivir
  • Focus : Manufacturer
  • Industry : Pharma

News about Medivir

Medivir

07-Nov-2012 | research and development

Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex

Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s ...

Read news
Medivir

24-Sep-2012 | research and development

Medivir: Phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055

Medivir AB announced that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial. ...

Read news
Medivir

07-Sep-2012 | business & finance

Medivir acquires preclinical antiviral programs including hepatitis C and prodrug technologies

Medivir AB announced that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property ...

Read news
Medivir

30-May-2012 | research and development

Medivir has initiated a phase I clinical trial with its cathepsin K inhibitor MIV-711

Medivir AB announced that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of ...

Read news
Medivir

18-May-2012 | people

New Executive Vice President Commercial for Medivir

Medivir AB announced that it has appointed Henric Juserius to be the new head of the company's commercial activities. Henric, who will have overall ...

Read news
Medivir

15-Mar-2012 | research and development

Medivir announces new studies in phase III program for TMC435

Study in previous non-responder Hepatitis C genotype-1 infected patients

Read news
Medivir

07-Dec-2011 | research and development

Medivir's TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients

Medivir AB announced that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company.  TMC435, a ...

Read news
Medivir

01-Sep-2011 | people

Medivir Strengthens its Management Team

Medivir AB announced several new appointments to its executive management team. Dr Maris Hartmanis has been appointed to Medivir’s management team as ...

Read news
Show more news about Medivir

Here you will find Medivir AB